background
delayedonset
urticari
maculopapular
rash
frequent
observ
children
treat
blactam
mani
label
allerg
without
reliabl
test
object
determin
etiolog
rash
explor
infecti
allerg
caus
method
children
present
emerg
depart
delayedonset
urticari
maculopapular
rash
enrol
acut
convalesc
sera
obtain
viral
screen
along
throat
swab
subject
underw
intraderm
patch
skin
test
blactam
month
present
antiblactam
blood
allergi
test
also
obtain
subject
underw
oral
challeng
test
oct
culprit
antibiot
result
eightyeight
children
enrol
posit
intraderm
posit
patch
test
posit
blood
allergi
test
subject
posit
oct
intradermalneg
intradermalposit
oct
reaction
sever
index
event
subject
least
posit
viral
studi
oct
neg
group
conclus
situat
blactam
allergi
clearli
overdiagnos
skin
rash
rare
reproduc
subsequ
challeng
viral
infect
may
import
factor
mani
rash
oct
posit
minor
intraderm
skin
testposit
subject
patch
test
blood
allergi
test
provid
use
inform
oct
consid
children
develop
delayedonset
urticari
maculopapular
rash
treatment
blactam
j
allergi
clin
immunol
antibiot
frequent
drug
prescrib
children
worldwid
blactam
prescrib
group
antibiot
somewher
g
g
per
peopl
per
day
prescrib
europ
children
treat
blactam
skin
rash
mostli
describ
maculopapular
urticari
frequent
report
primari
care
physician
rash
frequent
assum
drugrel
allergi
although
viral
infect
also
often
consid
differenti
diagnosi
suggest
rash
actual
allerg
origin
howev
clinic
practic
larg
major
children
label
penicillinallerg
without
appropri
test
mostli
fear
sever
allerg
reaction
time
diagnosi
persist
adulthood
result
may
deni
optim
antimicrobi
coverag
first
choic
antibiot
treatment
often
treat
costli
antibiot
averag
prescript
cost
higher
patient
suspect
penicillin
allergi
current
clear
figur
rate
true
penicillin
allergi
among
children
develop
rash
blactam
treatment
use
investig
protocol
patient
lack
sever
immunolog
mechan
caus
allergi
blactam
identif
igemedi
allergi
potenti
anaphylact
lifethreaten
reaction
essenti
type
reaction
gener
occur
within
hour
receiv
medic
classifi
immedi
reaction
incid
potenti
sever
reaction
low
nonimmedi
reaction
usual
manifest
maculopapular
urticari
rash
occur
hour
drug
intak
far
common
suspect
rash
tcellmedi
current
diagnosi
mostli
assess
use
skin
test
exclud
igemedi
allergi
neg
skin
test
patient
oral
challeng
test
oct
consid
gold
standard
occasion
perform
better
diagnosi
children
suspect
penicillin
allergi
would
directli
benefit
affect
children
provid
better
treatment
guidanc
physician
might
contribut
lower
health
cost
primari
aim
studi
investig
infecti
allerg
caus
urticari
maculopapular
skin
rash
children
treat
blactam
secondari
object
evalu
diagnost
accuraci
allergi
test
prospect
observ
studi
includ
consecut
children
refer
evalu
possibl
blactam
allergi
pediatr
emerg
depart
geneva
univers
hospit
studi
approv
ethic
committe
geneva
univers
hospit
switzerland
studi
subject
year
old
urticari
maculopapular
rash
hour
treatment
blactam
antibiot
patient
rash
clearli
suggest
childhood
infecti
diseas
rubella
measl
chicken
pox
scarlet
fever
relat
potenti
sever
reaction
steven
johnson
lyell
syndrom
drug
rash
eosinophilia
system
symptom
anaphylaxi
respiratori
cardiovascular
involv
exclud
investig
conduct
step
fig
inclus
visit
patient
underw
clinic
evalu
compos
medic
histori
physic
examin
pictur
skin
lesion
taken
urticaria
defin
dissemin
rapidli
evolv
transient
itchi
wheal
individu
lesion
last
less
hour
maculopapular
rash
defin
small
confluent
erythemat
macula
papul
persist
hour
also
dissemin
differ
part
bodi
blood
drawn
measur
antibodi
virus
known
associ
childhood
skin
rash
epsteinbarr
viru
ebv
human
herp
viru
cytomegaloviru
cmv
parvoviru
patient
also
throat
swab
respiratori
viru
screen
pcr
accord
previous
publish
method
virus
screen
via
throat
swab
includ
picorna
corona
human
metapneumoviru
bocaviru
influenza
parainfluenza
virus
second
visit
month
later
second
determin
viral
serolog
ebv
cmv
parvoviru
perform
patient
underw
complet
allergi
workup
follow
european
network
drug
allergyeuropean
academi
allergi
clinic
immunolog
guidelin
workup
subject
suspicion
nonimmedi
reaction
blactam
intraderm
skin
test
perform
forearm
penicilloylpolylysin
ppl
minor
determin
mixtur
mdm
diater
madrid
spain
standard
concentr
amoxicillin
clamoxyl
glaxosmithklin
munchenbuchse
switzerland
concentr
mgml
dilut
nacl
basi
experi
limit
pain
skin
test
perform
first
test
lower
concentr
mgml
cephalosporin
incrimin
workup
complet
intraderm
skin
test
solubl
form
suspect
drug
avail
ie
ceftriaxon
rocephin
roch
pharma
basl
switzerland
cefuroxim
zinacef
glaxosmithklin
concentr
mgml
skin
test
respons
assess
minut
wheal
equal
superior
mm
diamet
absenc
wheal
control
solut
diluent
diater
presenc
posit
respons
histamin
skin
prick
test
mgml
defin
immedi
posit
respons
patch
test
solut
prepar
mix
incrimin
drug
petrolatum
concentr
neg
control
perform
petrolatum
alon
individu
test
reagent
appli
uninvolv
skin
interscapular
region
patient
back
use
acryl
adhes
strip
small
plate
attach
test
allergen
iq
ultra
chamber
dormer
laboratori
rexdal
ontario
canada
skin
test
blood
sampl
taken
subject
vitro
assay
antigenspecif
ige
penicilloyl
g
penicilloyl
v
amoxicillin
perform
use
unicap
phadia
ab
uppsala
sweden
specif
ige
consid
neg
result
kul
oct
implic
blactam
drug
perform
children
strict
hospit
surveil
physician
full
resuscit
backup
oct
protocol
adapt
result
skin
test
follow
intraderm
skin
test
neg
patient
receiv
therapeut
dose
calcul
weight
amount
given
provid
safeti
margin
exclus
reaction
occur
higher
dose
skin
test
posit
initi
dose
therapeut
dose
administ
reaction
appear
minut
later
remain
therapeut
dose
given
patient
observ
hour
last
dose
involv
drug
therapeut
dose
given
home
hour
patient
without
immedi
reaction
third
visit
occur
day
later
patch
test
late
intraderm
skin
test
read
patch
test
read
minut
remov
strip
grade
recommend
sampl
size
calcul
control
accuraci
length
ci
estim
proport
real
allerg
reaction
children
develop
rash
blactam
treatment
primari
endpoint
basi
rate
describ
previou
studi
obtain
ci
around
expect
preval
sampl
size
requir
calcul
n
patient
characterist
describ
median
rang
frequenc
ci
proport
calcul
use
exact
method
clopperpearson
rate
posit
oct
compar
intraderm
test
use
fisher
exact
test
sensit
specif
posit
neg
predict
valu
intraderm
skin
test
patch
test
specif
ige
also
assess
patient
subgroup
test
cephalosporin
penicillin
given
ci
tabl
total
children
girl
boy
averag
age
year
rang
complet
visit
studi
twenti
patient
agre
allergi
workup
mostli
fear
pain
intraderm
skin
test
initi
reaction
patient
compar
complet
studi
requir
inclus
criteria
recruit
patient
initi
present
mild
nonimmedi
reaction
occur
definit
hour
last
dose
culprit
antibiot
amoxicillin
patient
amoxicillinclavulan
acid
patient
cephalosporin
patient
case
drug
administ
oral
patient
receiv
parenter
skin
reaction
diagnos
predominantli
urticari
patient
predominantli
maculopapular
patient
rash
appear
averag
day
sd
day
initi
treatment
last
mean
day
sd
day
second
visit
occur
averag
week
sd
week
index
event
intraderm
skin
test
posit
test
patient
wheal
size
greater
mm
patient
oct
incrimin
drug
carri
total
patient
reaction
reproduc
patient
amoxicillin
amoxicillinclavulan
acid
cephalosporin
tabl
ii
skin
rash
observ
oct
similar
initi
one
reaction
immedi
minut
patient
delay
other
mean
hour
rang
hour
subject
went
posit
oct
display
immedi
posit
respons
skin
test
reagent
tabl
iii
howev
patient
posit
intraderm
test
higher
rate
posit
oct
without
p
fisher
exact
test
overal
sensit
determin
intraderm
skin
test
specif
intraderm
skin
test
subgroup
patient
urticari
reaction
display
sensit
specif
wherea
patient
develop
j
allergi
clin
immunol
volum
number
maculopapular
rash
sensit
specif
patch
test
delay
intraderm
skin
test
neg
test
patient
includ
patient
posit
oct
serum
specif
ige
antibodi
titer
blactam
neg
kul
patient
patient
neg
oct
specif
ige
higher
kul
kul
histori
allergi
equal
preval
person
famili
histori
children
posit
neg
oct
result
screen
viral
infect
pcr
serum
antibodi
test
present
tabl
iv
viral
trigger
initi
rash
suspect
patient
neg
oct
virus
frequent
identifi
enterovirus
picornaviru
interestingli
patient
posit
oct
find
suggest
acut
ebv
infect
recent
ebv
infect
less
month
test
acut
ebv
infect
also
identifi
patient
neg
oct
prospect
studi
aim
find
caus
rash
children
present
treatment
blactam
drug
determin
risk
develop
similar
rash
rechalleng
antibiot
knowledg
first
prospect
studi
drug
allergi
preval
subject
regardless
skin
test
outcom
rechalleng
studi
rash
reproduc
oct
challeng
patient
ci
find
highli
relev
clinic
practic
patient
would
otherwis
fals
label
penicillinallerg
rash
frequent
childhood
estim
incid
approxim
case
per
mani
potenti
caus
pediatr
rash
especi
among
children
intercurr
ill
treat
antibiot
viral
infect
common
caus
maculopapular
urticari
erupt
independ
medic
rate
exanthema
viral
infect
highli
variabl
depend
viru
studi
screen
virus
commonli
known
associ
rash
use
pcr
serolog
analysi
vast
major
children
neg
subsequ
oct
test
posit
viral
infect
mostli
enterovirus
picornaviru
initi
visit
virus
could
caus
index
rash
patient
similar
nonimmedi
allerg
reaction
viralinduc
exanthema
immunolog
mediat
cell
play
central
role
howev
major
differ
shown
immunolog
mechan
suspect
neg
viral
screen
result
patient
subsequ
neg
oct
may
result
limit
test
techniqu
infecti
trigger
virus
screen
bacteri
infect
allerg
reaction
far
common
caus
rash
intak
blactam
antibiot
adult
children
reaction
refer
drug
allergi
immunolog
mechan
either
antibodymedi
cellmedi
demonstr
definit
reaction
reproduc
studi
reproduc
demonstr
low
proport
patient
potenti
drugrel
rash
inflammatori
reaction
infect
certainli
exclud
pathogenesi
cutan
drug
reaction
viral
infect
may
involv
viralinduc
polyclon
activ
lymphocyt
reaction
involv
cellular
immun
alter
drug
metabol
ebv
best
known
exampl
viral
risk
factor
cutan
drug
reaction
reaction
patient
subsequ
found
infect
ebv
tradit
consid
belong
drug
allergi
intrigu
result
studi
patient
posit
oct
test
posit
acut
ebv
infect
case
persist
ebvinduc
inflamm
could
favor
reaction
induc
oct
also
possibl
ebv
infect
might
chang
pattern
reactiv
antibiot
persist
delayedtyp
reaction
amoxicillin
instead
classic
transient
decreas
drug
toler
ebv
infect
report
although
conclus
specul
encourag
investig
patient
aminopenicillininduc
exanthema
ebv
infect
diagnost
allergi
workup
patient
develop
rash
remain
controversi
strongli
emphas
patient
histori
essenti
confirm
diagnosisfor
exampl
use
enda
questionnair
although
recent
studi
investig
diagnost
test
differenti
viral
druginduc
exanthema
test
valid
far
analysi
diagnost
valu
common
allergi
test
skin
test
specif
ige
hamper
surprisingli
low
number
patient
posit
oct
studi
show
good
specif
intraderm
skin
test
sensit
number
slightli
higher
previous
report
low
rate
reaction
skin
testposit
patient
reexposur
antibiot
also
report
other
retrospect
studi
current
guidelin
suggest
immedi
read
intraderm
skin
test
done
immedi
reaction
suspect
igemedi
studi
patient
develop
immedi
reaction
immedi
read
intraderm
test
consid
predict
immedi
reaction
sensit
would
even
lower
specif
previou
studi
found
high
neg
predict
valu
intraderm
skin
test
although
cell
clearli
demonstr
play
role
nonimmedi
reaction
patch
test
neg
patient
investig
may
explain
low
sensit
test
previous
observ
other
low
number
patient
posit
oct
serum
specif
ige
antibodi
titer
blactam
neg
patient
posit
oct
suggest
ige
measur
nonimmedi
reaction
use
oct
remain
gold
standard
diagnosi
drug
allergi
emphas
none
patient
posit
oct
develop
sever
reaction
index
event
recent
studi
patient
histori
nonlifethreaten
allerg
reaction
penicillin
show
posit
penicillin
skin
test
associ
higher
rate
posit
oct
penicillin
neg
skin
test
result
author
conclud
challeng
perform
patient
skin
test
feasibl
result
suggest
would
perform
pain
timeconsum
skin
test
children
predict
posit
challeng
patient
demonstr
oct
best
diagnost
npv
neg
predict
valu
ppv
posit
predict
valu
three
patient
posit
ppl
mdm
ppl
amoxicillin
ppl
mdm
amoxicillin
one
patient
posit
mdm
ppl
ppl
patient
posit
ppl
patient
react
cefuroxim
j
allergi
clin
immunol
volum
number
tool
benign
skin
rash
children
complet
allergi
workup
skin
test
specif
ige
measur
follow
oct
requir
patient
histori
suggest
anaphylaxi
protocol
includ
oct
reduc
risk
immedi
potenti
sever
allerg
reaction
patient
posit
skin
test
howev
none
patient
develop
immedi
andor
sever
reaction
thu
oct
patient
histori
benign
reaction
consid
safe
meantim
challeng
children
referr
clinic
protocol
follow
observ
without
signific
reaction
nevertheless
need
emphas
procedur
requir
care
primari
evalu
experienc
allergist
perform
patient
suspect
sever
reaction
conclus
children
present
benign
skin
rash
absenc
symptom
treat
blactam
suggest
perform
initi
oct
medic
supervis
follow
standard
blactam
dose
hour
home
protocol
proven
safe
effici
workup
possibl
reaction
antibiot
children
benign
rash
challeng
patient
benign
rash
avoid
deni
futur
use
blactam
antibiot
larg
number
patient
would
otherwis
diagnos
penicillin
allergi
